Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesMucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.The influence of delivery vectors on HIV vaccine efficacyA single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animalsStimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin.Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques.Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaquesVesicular stomatitis virus-simian retrovirus type 2 vaccine protects macaques from detectable infection and B-cell destructionNonsegmented negative-strand viruses as vaccine vectors.Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusCreation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectorsNeurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primatesFirst-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.Intranasal delivery of vaccines against HIV.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceRemoval of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesHuman immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Use of viral vectors for the development of vaccines.Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication.
P2860
Q21090120-C81186A4-3416-4EBD-8CB6-7FD3DB58311AQ21131585-0F516A0D-3271-4AF7-A99B-88498FF7E312Q22241377-A5571219-B3C8-4306-9470-9F9FE723EE6BQ27021839-35CA5DD3-4BA4-447D-BF7B-9B99AD601FA4Q30361939-552EE038-26E8-496D-A5AD-9F1449FDDC2DQ30373857-49226C49-4CF7-409C-AE18-D3739597E009Q30378897-44DA70C6-4655-4B93-B8F0-73F1A57652ACQ33653655-786FADF9-5391-4451-84A7-F07D1578FA0DQ33713083-984844F6-ACD6-4B18-A058-BCDD9A5177D7Q33721746-3CB6B44D-6E03-4EB3-A4DB-981C9C39C118Q33725635-33A64411-F0BD-471D-A2C2-ECF463C0B8B0Q33743852-14D809F3-0E3E-4A96-B3AA-9D273EA03A1DQ34077543-957C1DF9-D318-46EF-9EBF-A93C36E96DFCQ34092753-CE09B715-8F32-4642-8893-1B44083CF4D6Q34172295-19BE6749-FE74-4F30-A66D-EF0DAF486B55Q34228558-16F242BE-4396-4D64-BB6A-433C1F7ADE92Q34296055-41B5722A-CF16-4C1D-BB8A-FEE1FFF69D06Q34296144-05934899-A9E6-47AD-9AF5-FCEEEE8C4757Q34647625-5FE51D9D-8F8C-4DEA-A014-42995B76E013Q34701202-18ADAF0F-7CA4-40C3-8C63-E6CA47D701A5Q34809716-83FAE5ED-361E-4B9C-8FFD-C6AA35614668Q35077051-921E0728-F49B-4447-8302-4E44019FB1EBQ35139219-37560EA5-43F3-4E87-9533-E22FEDB53D1BQ35675044-3378709A-89E8-4F83-B229-59C72974B56DQ35760520-CA1D2DF2-28CE-4DB6-8E3C-A169E12D6F31Q35781967-89FC9508-3AEA-4CF8-BD65-99CDFF1803A9Q35858437-2DB278E4-DCCF-48B5-AD64-8F8D43EA0AA1Q36141610-0B61F2DD-AF91-438B-94C2-85611AFD9519Q36166161-0AAE39F6-4C08-473B-BA20-B6BFF25A4BBEQ36276936-4B2AE05F-693B-4458-AA36-6BB43C3EB4B5Q36409054-BF7F9DFD-D409-427F-A86A-5FC9742C1D60Q36423935-7C40A063-DFA8-4A27-BD00-71FC4548FC6FQ36424574-B02612AC-9EF3-4F8B-B990-015F86BEBFD7Q36498186-1C72DC14-1010-4F14-B805-53BAE796066DQ36780156-9C1A6BB1-358C-4D1D-A727-4547A83DAD40Q36898706-D6AF1F6B-AEE0-4E20-93CC-54C46BFA584CQ37066697-9F0FC12A-486A-4DAF-824A-2198E03ABCFCQ37355979-CCAC8288-2475-4701-A560-61AE5FE7EB61Q37427047-EE135E62-84CB-48F4-8BB9-FAECC37114F9Q39610541-1AFC1289-C8E3-48C5-BC73-88D1D129626D
P2860
Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Immunogenicity of attenuated v ...... ramuscular vaccination routes.
@en
Immunogenicity of attenuated v ...... ramuscular vaccination routes.
@nl
type
label
Immunogenicity of attenuated v ...... ramuscular vaccination routes.
@en
Immunogenicity of attenuated v ...... ramuscular vaccination routes.
@nl
prefLabel
Immunogenicity of attenuated v ...... ramuscular vaccination routes.
@en
Immunogenicity of attenuated v ...... ramuscular vaccination routes.
@nl
P2093
P356
P1476
Immunogenicity of attenuated v ...... ramuscular vaccination routes.
@en
P2093
Amjed Masood
Dana L Hasselschwert
David K Clarke
Eric M Mishkin
Eva B Schadeck
J Erik Johnson
John H Eldridge
John K Rose
Kevin J Lopez
Michael A Egan
P304
P356
10.1089/AID.2004.20.989
P577
2004-09-01T00:00:00Z